Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13103MR)

This product GTTS-WQ13103MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13103MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10620MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ11540MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ2042MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ2229MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ4240MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ4189MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ5608MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ4868MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW